anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Hepaticojejunostomy anastomosis (HJA) is the most challenging aspect in single-port laparoscopic choledochal cystectomy and Roux-en-Y hepaticojejunostomy (SPCH) in children, especially in small-diameter anastomoses (diameters less than 5 mm), which are more susceptible to anastomotic stricture. We developed the continuous submucosal technique for HJA (CS-HJA) to lessen postoperative complications. The purpose of this study is to introduce our preliminary experiences with CS-HJA.
METHODS: We retrospectively analyzed all available clinical data of children who underwent SPCH surgery between March 2020 and October 2022. We operated with CS-HJA on 10 children who were diagnosed with small-diameter hepaticojejunostomy (diameter less than 5 mm). Data collection mainly included demographic information, imaging data, perioperative details, and postoperative outcomes. Ten patients were included in this study. The average patient age was 55.2 months; the age range was 3 to 120 months, and the average weight was 11.6 kg; male-female ratio was 1:9. The choledocho had fusiform dilatation in five cases and cystic dilatation in five cases. There was no dilatation of the left and right hepatic ducts or intrahepatic bile ducts in all patients. All patients had no dilatation of the left and right hepatic ducts or intrahepatic bile ducts. All patients underwent a single-port laparoscopic bile-intestinal anastomosis using a submucosal jejunal anastomosis technique. Analysis of the duration of the bile-intestinal anastomosis, the length of the child's stay in the hospital after surgery, the intraoperative complications, and the postoperative complications was performed.
RESULTS: All the 10 patients underwent successful SPCH by CS-HJA technique. The average length of time for hepaticojejunostomy ranged from 22 to 40 minutes, and the postoperative hospital stay was 5.2 to 9.2 days. There were no instances of bile leakage following the operation. At 17 to 30 months of follow-up, there was no abdominal pain or jaundice, and the reexamination of transaminases, bilirubin, and amylase were normal. Ultrasonography showed no bile duct stricture or dilated bile ducts, and the incision is elegant, and the families of the patients were satisfied.
CONCLUSION: In SPCH surgery in children, the CS-HJA technique is safe and feasible for small-diameter hepaticojejunostomy.
Composition comprises at least one hydroquinone diphosphate compound (I) or its salt, its solvates including hydrates, and its optical and geometric isomers, in a medium. Composition comprises at least one hydroquinone diphosphate compound of formula (I) or its salt, its solvates including hydrates, and its optical and geometric isomers, in a medium. R, R 3phosphate group; R 1, R 2H or linear 1-6C, or branched 3-6C alkyl group, optionally substituted by -COOR 4or -CONR 4R 5; and R 4, R 5H or 1-4C alkyl group. An independent claim is included for the hydroquinone diphosphate compound of formula (I). [Image] ACTIVITY : Dermatological. MECHANISM OF ACTION : Tyrosinase inhibitor. The ability of (I) to inhibit tyrosinase was tested in keratinocyte and melanocyte coculture. The results showed that hydroquinone 1,6-O-diphophate tetrasodium salt exhibited an IC 5 0value of 50 mu m.
Controls: Post-menopausal females between 50-80 years who have not experienced a fracture at any site after the age of 40 years (does not include fractures of the digits, toes or face). Does not self-report losing more than 1.5 inches in stature (height) in the previous 15 years. Body mass index between 18.5 and 35 kg/m2.
A composition provides an isotonic nasal irrigation solution with pH less than about 7.0. The composition may be formed of a salt and a pH buffer and may include an additive. The composition may be mixed with water to form the solution. The composition may aid in the treatment of various nasal or sinus disorders such as, for example, dryness, rhinitis, and sinusitis. The isotonic irrigation solution may also aid in the removal of contaminants from the sinus and nasal cavities such as blood, mucus, dirt, pollen, allergens, viruses, and bacterial. The composition may be liquid or dry.
PURPOSE: To obtain a diphenyldisulfide compound having excellent inhibitory action on IL-1β production and on TNFαliberation, low toxicity and effective for preventing and treating septicemia, chronic rheumatoid arthritis, etc. CONSTITUTION: This compound is shown by formula I (R1 is imidazolyl, pyrazolyl, etc., R2 is imidazolinyl, pyrazolinyl, etc.; R3 and R4 are each H, methyl, n-propyl, etc.). The compound is obtained by reacting 1mol of a di(2- aminophenyl)disulfide compound of formula II with 0.5-4mol of a compound of the formula R'Hal (R' is a halide of a 5-membered or 6-membered heterocyclic compound containing two nitrogen atoms as hetero atoms, etc.) to monosubstitute heterocyclic groups for the two amino groups of the compound of formula II. The reaction is preferably carried out in an inert organic solvent such as methanol in the presence of a base such as NaOH at a normal temperature to the boiling temperature of the solvent.
There is longstanding evidence that tuberculosis (TB) transmission is not from TB patients on effective treatment, but from unsuspected cases, and cases with unsuspected drug resistance. This study seeks to investigate the implementation of a refocused TB transmission control approach that we call FAST (Find cases Actively based on cough surveillance, Separate temporarily, and Treat effectively based on molecular drug-susceptibility testing \[DST\]). We will conduct this study at Hospital Nacional Hipólito Unanue in Lima, Peru. Our hypothesis is that FAST will reduce delays in identifying infectious TB patients (and unsuspected drug resistance) entering the hospital, facilitate timely effective therapy, and thereby reduce the risk of TB transmission in a cost-effective manner. We will assess the impact of FAST on TB transmission by evaluating IGRA conversions among health care workers at the intervention site, Hospital Nacional Hipolito Unanue (HNHU), and two control sites, Hosptial Nacional Arzobispo Loayza (HNAL) and Hospital Nacional Sergio Bernales (HNSB). We will also evaluate acceptability and barriers to/facilitators of FAST, novel screening strategies, and health care worker IGRA testing using a mixed methods approach.
In patients with moderate (CLcr = 30-50 ml/min) to severe (CLcr<30 ml/min) renal impairment, the AUC of vardenafil was 20 – 30% higher compared to that observed in a control group with normal renal function (CLcr>80 ml/min) (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations). Vardenafil pharmacokinetics have not been evaluated in patients requiring renal dialysis.

General: In humans, vardenafil alone in doses up to 20 mg does not prolong the bleeding time. There is no clinical evidence of any additive prolongation of the bleeding time when vardenafil is administered with aspirin. Vardenafil has not been administered to patients with bleeding disorders or significant active peptic ulceration. Therefore LEVITRA should be administered to these patients after careful benefit-risk assessment.

Treatment for erectile dysfunction should generally be used with caution by patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) or by patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

The safety and efficacy of LEVITRA used in combination with other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.
The invention belongs to the technical field of medicine, and discloses fusidic acid chemically modified compounds, and a preparation method and an application thereof. The fusidic acid chemically modified compounds have a structure represented by a formula 1. In the formula 1, R1 and R2 are hydrogen atom, halogen, alkoxy, trifluoromethyl or alkyl. According to the invention, a natural product, namely fusidic acid, is subjected to chemical modification, such that a series of fusidic acid derivatives are obtained. The method has the advantages of simple preparation method and high synthesis yield. The obtained fusidic acid is chemically modified, and the chemically modified fusidic acid can be widely applied. Pharmacological experiments show that part of the fusidic acid chemically modified derivatives have a significant effect in inhibiting bacterial (such as Wolbach phage) activity, which means the type of compounds can be applied in preparing medicines used for preventing, controlling or treating bacterial infections. The compounds can also be used as additives for preparing medical instruments with sterilization and disinfection functions.
Pulmonary hamartomas are abnormal growths of mature cell or tissue types, including cartilage, epithelium, fat or muscle. Although most cases are benign, asymptomatic and often incidentally discovered, these masses may provoke significant complications via predisposition to obstruction, ischaemia or infection. Pulmonary hamartomas located within the tracheal lumen are exceedingly rare clinical entities which produce symptoms of dyspnoea, cough, stridor, wheezing or angina. Significant clinical consequences include airway obstruction and cardiovascular collapse. Most cases of tracheal hamartoma are initially diagnosed as obstructive pulmonary disease. We present a structured case report of a tracheal hamartoma identified in a patient with recent coronary artery bypass grafting who was initially evaluated for persistent ischaemic pathology, resulting in delay of diagnosis. By review of limited literature of this disorder, we emphasise the need for clinicians to be aware of this indolent and rare entity.
According to the disclosed present invention, a sun stick mold using air pressure comprises: a product molding frame; a plurality of air supplying holes; and a guide unit. The product molding frame combines a container with an end unit, and allows at least one product molding groove to be formed to mold a face surface of contents of the sun stick. The plurality of air supplying holes are formed at a predetermined interval along an edge of the product molding groove to be connected from a bottom surface of the product molding frame to the product molding groove. The guide unit is mounted on the product molding frame and separates contents of the sun stick by blocking an air path of the air supplying holes and discharging air to an upper part when the container is combined with a penetrating hole formed to cover the product molding groove. The present invention supplies the air through the air supplying holes formed along an edge of the face surface of the contents of the sun stick molded by the product molding groove of the product molding frame, blocks the air path of the air supplying holes through the penetrating hole of the guide unit, and separates the contents of the sun stick in an air discharging step. Therefore, an extraction defect rate can be improved.
INTRODUCTION: Many patients with muscle-invasive bladder cancer are poor candidates for radical cystectomy or trimodality therapy with maximal transurethral resection of bladder tumor (TURBT) and chemoradiotherapy with cisplatin or mitomycin C. Given the benefit of chemotherapy in bladder-preserving therapy, less-intense concurrent chemotherapy regimens are needed. This study reports on efficacy and toxicity for patients treated with trimodality therapy using single-agent concurrent capecitabine.
MATERIALS AND METHODS: Patients deemed ineligible for radical cystectomy or standard chemoradiotherapy by a multidisciplinary tumor board and patients who refused cystectomy were included. Following TURBT, patients received twice-daily capecitabine (goal dose 825 mg/m2) concurrent with radiotherapy to the bladder +/- pelvis depending on nodal staging and patient risk factors. Toxicity was evaluated prospectively in weekly on-treatment visits and follow-up visits by the treating physicians. Descriptive statistics are provided. Overall, progression-free, cancer-specific, distant metastasis-free, and bladder recurrence-free survival were estimated using the Kaplan-Meier method.
RESULTS: Twenty-seven consecutive patients met criteria for inclusion from 2013 to 2023. The median age was 79 with 9 patients staged cT3-4a and 7 staged cN1-3. The rate of complete response in the bladder and pelvis was 93%. Overall, progression-free, cancer-specific, distant metastasis-free, and bladder recurrence-free survival at 2 years were estimated as 81%, 65%, 91%, 75%, and 92%, respectively. There were 2 bladder recurrences, both noninvasive. There were 7 grade 3 acute hematologic or metabolic events but no other grade 3+ toxicities.
CONCLUSION: Maximal TURBT followed by radiotherapy with concurrent capecitabine offers a high rate of bladder control and low rates of acute and late toxicity.
The invention relates to a synthesis process for fenticonazole nitrate. In the synthesis process, thiophenol and para aminobenzoic acid are taken as raw materials, and are subjected to seven-step reaction to form the fenticonazole nitrate, and the yield is higher. The invention relates to a preparation method for a levorotatory form and a dextrorotatory form of the fenticonazole nitrate, which solves the problem that the levorotatory form and the dextrorotatory form cannot be well obtained due to complicated and fussy operation according to documents. The levorotatory form and the dextrorotatory form have high purity and high industrial application value. Experiments prove that the antibacterial activity of the levorotatory form of the fenticonazole nitrate is greater than that of racemate and the dextrorotatory form. The invention relates to application of the levorotatory form of the fenticonazole nitrate in preparing antifungal medicaments.
<P>PROBLEM TO BE SOLVED: To provide a tumor suppressor gene useful for diagnosing and treating cancers.  <P>SOLUTION: A specific region of chromosome 10 (10q23.3) has been implicated to contain a tumor suppressor gene and a corresponding coding region of the gene represents a new 47 kD protein. A domain of the product has an exact match to a conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses have demonstrated that a number of exons of the gene are deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of the gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of deletions in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to the tumor suppressor (designated as TS10q23.3) are also disclosed.  <P>COPYRIGHT: (C)2010,JPO&INPIT
OBJECTIVE: Docosahexaenoic acid (DHA) is recommended routinely in pregnancy to promote fetal development. DHA has anti-inflammatory activity, but its effects on the fetal heart and circulation are unknown. This study aimed to investigate whether maternal DHA supplementation in the third trimester affects maternal prostaglandin levels and fetal ductus arteriosus flow dynamics.
METHODS: This was a double-blind randomized controlled trial with parallel groups conducted between 2018 and 2021. Pregnant women aged over 18 years with a normal fetus at 27-28 weeks' gestation showing no cardiac/extracardiac anomalies or ductal constriction were eligible for the trial. Women consuming substances with a known inhibitory effect on prostaglandin metabolism, such as non-steroidal anti-inflammatory drugs and polyphenol-rich foods, were excluded. The intervention group received oral supplementation of omega-3 with 450 mg/day of DHA for 8 weeks and the placebo group received capsules of soy lecithin for 8 weeks. Anthropometric measurements, assessment of polyphenol and omega-3 consumption, fetal morphological ultrasound examination, fetal Doppler echocardiographic examination and blood sample collection were performed at the start of the study and the latter two were repeated at follow-up. Prostaglandin E2 (PGE2) level and echocardiographic parameters were compared between the intervention and placebo groups and between baseline and follow-up.
RESULTS: A total of 24 participants were included in each group. After 8 weeks, there were no significant differences between the intervention and placebo groups in maternal serum PGE2 level or Doppler echocardiographic parameters of ductal flow. No case of ductus arteriosus constriction was observed. The expected intragroup changes in cardiac morphology, as a result of advancing gestation, were present.
CONCLUSIONS: Maternal DHA supplementation in the third trimester at a clinically recommended dose did not result in inhibition of PGE2 or constriction of the ductus arteriosus. These findings should be confirmed in postmarket surveillance studies with larger patient numbers in order to test the full safety profile of DHA and provide robust clinical reassurance. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
The utilisation of atropine drops is a common practise in order to induce pupil dilatation, impede accommodation, and decelerate the advancement of myopia. Research findings indicate that the treatment of atropine at a low concentration of 0.01% has been observed to effectively slow down the advancement of myopia, with a reduction rate ranging from 60% to 83%. The administration of a lesser dose of atropine demonstrates a decreased occurrence of undesirable effects in comparison to the administration of atropine at a high concentration of 1.0%. Nevertheless, it is crucial to acknowledge that even when present in low concentrations, atropine still exerts an influence on both pupil size and pupil responsiveness. This investigation employs a prospective cohort study design, in which a set of objective and subjective assessments will be carried out before and after the injection of 0.01% atropine for a duration of 18 hours. The main aim of this study is to determine the effects of a specific concentration of atropine on several factors, including: 1) visual acuity; 2) pupil diameter; 3) subjective perception of vision quality; and 4) intraocular pressure. The objective of this study is to examine the effects of the eye drops on ocular health and determine the degree of patient acceptance about their prospective use as a preventive measure for myopia. The researchers have a positive expectation that the administration of the drops will have minimal influence on the participants in terms of side effects. However, the outcomes of this study will provide valuable insights for children and patients in effectively managing the side effects associated with the use of atropine for myopia control.
Post-partum haemorrhage (PPH) remains a leading cause of maternal morbidity and mortality. Haemostasis and fibrinolysis are activated in peripartum. Fibrinolysis is decreased during pregnancy, is quickly activated after childbirth and can be overactivated in case of PPH. Tranexamic acid (TXA), an antifibrinolytic drug, has been proven to efficiently decrease bleeding and death in PPH. Its place in prevention of PPH after caesarean section remains to be established. The aim of the study protocol TRAAP2 is to conduct a large multicentre randomized, double blind placebo-controlled trial to adequately assess the impact of TXA for preventing PPH following a caesarean section. Peripartum is also a period of increased thrombo-embolic risk. TXA has never been proven to increase thromboembolic events. Nevertheless, it seems important to reserve TXA for women with activated fibrinolysis.

The aim of the ancillary biologic study BIO-TRAAP is thus to explore haemostasis and fibrinolysis in peripartum, to determine which women will in the future benefit from TXA. Fibrinolysis will be studied by clot lysis time by Global Fibrinolytic Capacity test on the Lysis Timer (GFC/LT), t-PA, PAI-1, PAI-2, euglobulin clot lysis time, plasminogen, plasmin-anti-plasmin complex, thrombin-anti-thrombin complex, fibrin degradation products (FDP).
The invention discloses gene engineering tumor targeted polypeptide and a preparation method and application thereof. In the method,  a polypeptide is seperated, thesequence of the polypeptide is an amino acid sequence shown in SEQ ID NO: 1. A primer that the gene engineering relates to inserts a nucleotide sequence of KCT-W1 into an expression vector pGEX-6p-1 to form recombinant expression plasmids; the recombinant expression plasmids transform colon bacillus Rossetta(DE3) and then obtain recombinant KCT-W1 polypeptide through cell lysis and GST affinity chromatography, the cutting of small intestine kinase and chromatogram purification. Cy5.5NHS easter is used to mark the KCT-W1 polypeptide to obtain a steady KCT-W1 polypeptide fluorescence complex. The KCT-W1 polypeptide fluorescence complexhas special target function for neuroglioma transplanted under the oxter of a big mouse, and can perform accurate tracing and positioning to tumor. The invention also discloses a use of the KCT-W1 polypeptide fluorescence complex in the preparation of medicine used to treat or prevent incipient tumor. The method is simple and easy, convenient in operation, highly efficient and sensitive.
There is a significant burden of cardiovascular disease morbidity and mortality in the end-stage kidney disease population, driven by traditional and non-traditional risk factors. Despite its prevalence, heart failure is difficult to diagnose in the dialysis population due to overlapping clinical presentations, limitations of investigations, and the impact on the cardiorenal axis. 'Foundation therapies' are the key medications which improve patient outcomes in heart failure with reduced ejection fraction and include beta-blockers, renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors. They are underutilised in the dialysis population due to the exclusion of chronic kidney disease patients from major trials and legitimate clinical concerns e.g. hyperkalaemia, intradialytic hypotension and residual kidney function preservation. A coordinated cardiorenal multidisciplinary approach can guide appropriate diagnostic considerations (biomarkers interpretation, imaging, addressing unique complications of kidney disease), optimise dialysis management (prescription length, frequency and ultrafiltration targets) and when at euvolaemia facilitate the stepwise introduction of appropriate foundation therapies.
The invention relates to soft traditional Chinese medicine composition capsules for treating cold. The soft traditional Chinese medicine composition capsules for treating cold are characterized in that the ingredients contained in capsule liquid include 30%-50% of traditional Chinese medicine extracts, 40%-70% of dispersing agent, 0%-6% of suspending agent and 0%-4% of wetting agent. The traditional Chinese medicine extracts include a dry extract and volatile oil which are prepared by, by weight, 50-200 parts of forsythia suspensa, 50-200 parts of notopterygium roots, 20-150 parts of mint, 50-200 parts of common andrographis herb, 20-150 parts of Chinese trichosanthes roots and 40-200 parts of dayflower. The soft capsules are produced after a countercurrent extraction process is adopted for extraction, extraction efficiency is high, energy is saved, the produced soft capsules are good in sealing performance, and objectionable odor of the medicines is masked. The soft traditional Chinese medicine composition capsules are good in medicine stability, do not absorb moisture and meanwhile have the advantages of being high in disintegration speed and bioavailability and the like. The virus cold treating effect of the soft capsules is remarkably superior to that of antiviral particles and is further superior to that of a traditional water-soluble preparation.